Figure3_Raw CT data

<b>Figure 4. mRNA for four of predicted GOI are altered in human sAD2.1 iPSNs compared to control AX0018 iPSNs. a-b. </b>Quantitative immunocytochemistry showing significant increase of pS199/pS202 (AT8) tau in βIII-tubulin (neuronal marker) positive sAD2.1 iPSNs compared to control AX0018 iPSNs. <b>c-d. </b>Western blot and quantification showing significantly increased levels of total, pS199/pS202 (AT8), and pT231 (AT180) positive tau levels in sAD2.1 iPSNs compared to control AX0018 iPSNs. <b>e. </b>Quantitative real-time PCR analysis showing two folds increase in the mRNA levels of RAB40A, SCGB3A1, TMEFF2, and a fold decrease in FRRS1 in sAD2.1 iPSNs compared to AX0018 control iPSNs. Data shown are mean + s.e.m; Two-tailed <i>t </i>tests welch-corrected; *p&lt;0.05; **p&lt;0.01, ***p&lt;0.005, n=3 biological replicates; n=3 technical replicates.